Zogenix Funding & Investors
Emeryville, CA
Zogenix, Inc. operates as a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company offers product candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.
zogenix.comTotal Amount Raised: $1,520,577,664
Zogenix Funding Rounds
Post Ipo Debt
$230,000,000
Post Ipo Equity
$230,253,000
Post Ipo Equity
$312,000,000
Post Ipo Equity
$288,937,500
Post Ipo Equity
$69,000,000
Post Ipo Equity
$98,325,000
Post Ipo Equity
$60,000,000
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
HealthCare Royalty PartnersSeries Unknown
$15,000,000
Series Unknown Investors
Oxford FinanceDomain AssociatesScale Venture PartnersClarus VenturesChicago Growth PartnersThomas McNerney & PartnersAbingworthDebt Financing
$35,000,000
Debt Financing Investors
Oxford FinanceFirst Citizens BankIPO
Unknown
Series B
$35,004,188
Series B Investors
Chicago Growth PartnersSeries B
$35,957,968
Series B Investors
Domain AssociatesClarus VenturesScale Venture PartnersOxford FinanceAbingworthDebt Financing
$3,100,000
Series B
$18,000,000
Series B Investors
AbingworthClarus VenturesScale Venture PartnersDomain AssociatesSeries A
$60,000,000
Series A Investors
Clarus VenturesDomain AssociatesThomas McNerney & PartnersScale Venture PartnersLife Science Angels